Annual Statement of Changes in Beneficial Ownership (5)
15 Février 2022 - 12:53AM
Edgar (US Regulatory)
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
[ ]
Form 3 Holdings Reported
[X]
Form 4 Transactions Reported
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0362
Estimated average burden hours per response...
1.0
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
SILBER ALLAN C | 2. Issuer Name and Ticker or Trading SymbolPOINT Biopharma Global Inc. [PNT] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
4850 WEST 78TH STREET | 3. Statement for Issuer's Fiscal Year Ended (MM/DD/YYYY) 12/31/2021 |
(Street)
INDIANAPOLIS, IN 46268
(City)
(State)
(Zip)
| 4. If Amendment, Date Original Filed(MM/DD/YYYY) | 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form Filed by One Reporting Person
___ Form Filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any | 3. Trans. Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
Amount | (A) or (D) | Price |
Common Stock | 6/30/2021 | | A4 | 313884 | A | (1) | 313884 | I | By Spouse |
Common Stock | 6/30/2021 | | J4 (2) | 23309 | D | $0 | 514778 | I | Trustee (3) |
Common Stock | | | | | | | 4218605 | D | |
Common Stock | | | | | | | 4035655 | I | Silber Holdings, Inc. (4) |
Common Stock | | | | | | | 71744 | I | Anglian Holdings, LLC (5) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (MM/DD/YYYY) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
(A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | On June 30, 2021, POINT Biopharma Global Inc. (f/k/a Therapeutics Acquisition Corp., the "Issuer") consummated a business combination (the "Business Combination") pursuant to which Bodhi Merger Sub, Inc., a wholly-owned subsidiary of the Issuer, merged with and into POINT Biopharma Inc. ("Old POINT"). At the effective time of the Business Combination, each share of Old POINT outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an implied Old POINT vested equity value of $585,000,000. As a result, the Reporting Person's spouse received the reported shares of the Issuer's Common Stock in consideration for the equity securities of Old POINT held by the Reporting Person's spouse prior to the Business Combination. These shares held by the Reporting Person's spouse were inadvertently omitted from the Form 4 filed by the Reporting Person on June 30, 2021. |
(2) | On June 30, 2021, the Reporting Person, as trustee, distributed 23,309 shares of the Issuer's Common Stock held pursuant to a trust to certain beneficiaries of that trust. This disposition was inadvertently omitted from the Form 4 filed by the Reporting Person on June 30, 2021. |
(3) | Held in a trust for which the Reporting Person is the trustee. |
(4) | Silber Holdings, Inc is a corporation controlled by the Reporting Person. |
(5) | Anglian Holdings, LLC is a limited liability company solely owned by the Reporting Person. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
SILBER ALLAN C 4850 WEST 78TH STREET INDIANAPOLIS, IN 46268 | X | X |
|
|
Signatures
|
William L. Demers, by Power of Attorney for Allan C. Silber | | 2/14/2022 |
**Signature of Reporting Person | Date |
Therapeutics Acquisition (NASDAQ:TXAC)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Therapeutics Acquisition (NASDAQ:TXAC)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024